Advertisement
ANAB vs ORKA
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ANAB is a Buy and ORKA is a Buy.
ANAB sees its Stochastic Oscillator climbs out of oversold territory
On November 10, 2026, the Stochastic Oscillator for ANAB moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 60 instances where the indicator left the oversold zone. In 49 of the 60 cases the stock moved higher in the following days. This puts the odds of a move higher at over 82%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ANAB's RSI Indicator exited the oversold zone, 15 of 22 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 68%.
The Moving Average Convergence Divergence (MACD) for ANAB just turned positive on October 15, 2026. Looking at past instances where ANAB's MACD turned positive, the stock continued to rise in 42 of 52 cases over the following month. The odds of a continued upward trend are 81%.
Following a +4.15% 3-day Advance, the price is estimated to grow further. Considering data from situations where ANAB advanced for three days, in 219 of 277 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 04, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ANAB as a result. In 74 of 93 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 80%.
The 50-day moving average for ANAB moved below the 200-day moving average on November 06, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ANAB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
The Aroon Indicator for ANAB entered a downward trend on October 29, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 35 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 36 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is 49 (best 1 - 100 worst), indicating steady price growth. ANAB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 94 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: ANAB's P/B Ratio (108.938) is slightly higher than the industry average of (3.498). P/E Ratio (-45.539) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (6.614) is also within normal values, averaging (440.869).
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
ORKA's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for ORKA turned positive on October 21, 2026. Looking at past instances where ORKA's MACD turned positive, the stock continued to rise in 43 of 54 cases over the following month. The odds of a continued upward trend are 80%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 26, 2026. You may want to consider a long position or call options on ORKA as a result. In 66 of 99 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 67%.
ORKA moved above its 50-day moving average on October 26, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for ORKA crossed bullishly above the 50-day moving average on November 02, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 73%.
Following a +6.46% 3-day Advance, the price is estimated to grow further. Considering data from situations where ORKA advanced for three days, in 205 of 260 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
Bearish Trend Analysis
The RSI Indicator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 13 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ORKA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 74%.
ORKA broke above its upper Bollinger Band on October 26, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for ORKA entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 4 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.127) is normal, around the industry mean (3.498). P/E Ratio (-50.422) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. ORKA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 61 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ORKA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
ANAB | ORKA | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 32 | 46 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 94 Overvalued | 4 Undervalued | |
PROFIT vs RISK RATING 1..100 | 36 | 100 | |
SMR RATING 1..100 | 99 | 94 | |
PRICE GROWTH RATING 1..100 | 49 | 34 | |
P/E GROWTH RATING 1..100 | 35 | 61 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ORKA's Valuation (4) in the null industry is significantly better than the same rating for ANAB (94) in the Biotechnology industry. This means that ORKA’s stock grew significantly faster than ANAB’s over the last 12 months.
ANAB's Profit vs Risk Rating (36) in the Biotechnology industry is somewhat better than the same rating for ORKA (100) in the null industry. This means that ANAB’s stock grew somewhat faster than ORKA’s over the last 12 months.
ORKA's SMR Rating (94) in the null industry is in the same range as ANAB (99) in the Biotechnology industry. This means that ORKA’s stock grew similarly to ANAB’s over the last 12 months.
ORKA's Price Growth Rating (34) in the null industry is in the same range as ANAB (49) in the Biotechnology industry. This means that ORKA’s stock grew similarly to ANAB’s over the last 12 months.
ANAB's P/E Growth Rating (35) in the Biotechnology industry is in the same range as ORKA (61) in the null industry. This means that ANAB’s stock grew similarly to ORKA’s over the last 12 months.
| ANAB | ORKA | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 68% | 2 days ago 77% |
| Stochastic ODDS (%) | 2 days ago 82% | 2 days ago 77% |
| Momentum ODDS (%) | 2 days ago 80% | 2 days ago 67% |
| MACD ODDS (%) | 2 days ago 81% | 2 days ago 80% |
| TrendWeek ODDS (%) | 2 days ago 82% | 2 days ago 73% |
| TrendMonth ODDS (%) | 2 days ago 81% | 2 days ago 76% |
| Advances ODDS (%) | 2 days ago 79% | 2 days ago 79% |
| Declines ODDS (%) | 7 days ago 82% | 27 days ago 74% |
| BollingerBands ODDS (%) | N/A | 2 days ago 85% |
| Aroon ODDS (%) | 2 days ago 85% | 2 days ago 71% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ANAB’s FA Score shows that 0 FA rating(s) are green while ORKA’s FA Score has 1 green FA rating(s).
- ANAB’s FA Score: 0 green, 5 red.
- ORKA’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ANAB’s TA Score shows that 4 TA indicator(s) are bullish while ORKA’s TA Score has 5 bullish TA indicator(s).
- ANAB’s TA Score: 4 bullish, 4 bearish.
- ORKA’s TA Score: 5 bullish, 5 bearish.
Price Growth
ANAB (@Biotechnology) experienced а +1.36% price change this week, while ORKA (@Biotechnology) price change was +9.99% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.
Reported Earning Dates
ORKA is expected to report earnings on Mar 11, 2027.
Industries' Descriptions
@Biotechnology (+4.90% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
ORKA and
Correlation & Price change
A.I.dvisor indicates that over the last year, ORKA has been loosely correlated with SYRE. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if ORKA jumps, then SYRE could also see price increases.
| Ticker / NAME | Correlation To ORKA | 1D Price Change % | ||
|---|---|---|---|---|
| ORKA | 100% | +4.72% | ||
| SYRE - ORKA | 51% Loosely correlated | -4.15% | ||
| XNCR - ORKA | 48% Loosely correlated | +2.07% | ||
| DNTH - ORKA | 44% Loosely correlated | -1.32% | ||
| CGON - ORKA | 43% Loosely correlated | -2.81% | ||
| JBIO - ORKA | 43% Loosely correlated | +5.13% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| LNGX | 43.00 | 0.87 | +2.06% |
| Global X U.S. Natural Gas ETF (LNGX) | |||
| BRKC | 43.07 | 0.51 | +1.21% |
| YieldMax BRK.B Option Income Strategy ETF (BRKC) | |||
| FISR | 24.77 | -0.14 | -0.56% |
| State Street Fixed Income Sector Rotation ETF (FISR) | |||
| CGCP | 21.50 | -0.15 | -0.69% |
| Capital Group Core Plus Income ETF (CGCP) | |||
| XPAY | 49.17 | -1.15 | -2.29% |
| Roundhill S&P 500 Target 20 Managed Distribution ETF | |||